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Abstract: 
          The physician-patient relationship has continued to face problems set by the imbalance in 
the informed consent.  Due to lack of informed dialogue, greater cultural competency and 
awareness, this issue is evident even today with the vast discrepancy that exists in the 
prescription process of medications and the non-adherence of patients with different religious 
backgrounds. Several physicians believe it is essential to have at least a minimal level of 
knowledge about various religious sensitivities so that negative impact on compliance is 
prevented. Many religious groups such as the Orthodox Christians, Muslims, Jews and Seventh 
Day Adventists have dietary restrictions that prevent them from taking some medications due to 
various ingredients in them. Much customer behavior is influenced by religion.  
If physicians give their patients the alternative of taking medications other than the ones 
with such contents, then the patients would be better able to determine their own modes of 
treatment. However, if physicians take such measures, it is important to note that medications 
must then clearly state their ingredients. The history of labeling has been one of many lengthy 
procedures and time span. However, goals were set, achieved, and implemented although it took 
a  long  time.  Similarly,  if  measures  are  taken  to  set  goals  to  provide  better  alternatives  of 
medications  for  patients  with  special  dietary  restrictions,  the  inequity  in  prescription  and 
compliance would narrow.   
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Introduction:  
 
  Since the formalized introduction of Medical Ethics in 1803, the physician-patient 
relationship has continued to face problems set by the imbalance in the informed consent.  Some 
of these problems were exacerbated by the laws enacted during approval processes of drugs and 
their labeling. Due to tragedies like the elixir incident of 1937, physicians gained more authority 
giving patients even less freedom and autonomy to develop a more informed dialogue with their 
doctors and get complete thorough care.  Due to lack of informed dialogue, greater cultural 
competency and awareness, this issue is evident even today with the vast discrepancy that exists 
in the prescription process of medications and the non-adherence of patients with different 
religious backgrounds. 
Several cases have been reported where patients from various religious backgrounds, 
including Muslims, Orthodox Christians, and Seventh Day Adventists, have discontinued 
medications due to inert medication ingredients such as pork or beef gelatin and or stearic acid, 
which led to the relapse of their diseases
1. Gelatin is one of the most controversial ingredients 
amongst the Jewish and Muslim communities. It is a protein obtained from animal (usually cows 
or pigs) tissues such as bone and skin. The gelatin content information is usually available in 
medication reference texts and from pharmaceutical manufacturers
2. The relapse of diseases due 
to this discontinuation makes it a matter that can not be ignored. Several physicians believe it is 
essential to have at least a minimal level of knowledge about various religious sensitivities so 
that negative impact on compliance is prevented.  
                                                 
1 Sattar, S.P. The Annals of Pharmacotherapy. 2004; Vol. 38, No. 4, pp. 621-624. 
2 Pinals, D and Sattar, S.P. Psychiatric Services. 2002 Vol. 53 No. 2  
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For example, Jehovah Witnesses refrain from taking blood derived products
3 and Jewish 
patients  avoid  oral  medications  containing  products  such  as  glycerol,  stearates,  lactose  and 
porcine
4. Muslim patients refrain from taking medications with pork or alcohol contents. Thus 
medications containing lard, gelatin (unless beef specified), non-soy lecithin, and alcohol are all 
ingredients in products that Muslims refrain from using
5.   If religious prohibitions due to certain 
inert products are one of the many reasons for non-compliance to medication in patients, then it 
would be interesting to discover if such gaps in prescription and adherence could be narrowed 
with a more thorough approach to informed consent and better labeling of these products in 
prescription medications.  
For example, it has been found that much of customer behavior is influenced by religion. 
When Dannon yogurt first obtained Kosher certification, sales increased approximately 25% 
amongst the Jewish population in the United States
6. Furthermore, another study showed that 
although patients give preference to quality of doctors and hygiene of the hospital, a greater 
proportion chooses a hospital with a similar religious affiliation as the patient
7. It may be inferred 
from such findings that one of the reasons for this choice is based upon a level of understanding 
patients feel physicians may have if they share a common religious faith or culture. It may be 
easier for a healthcare provider to deal with the patient if he or she understands the faith, values 
and culture of his or her patient. Another study showed that physicians achieved better and 
improved compliance with patients of Hispanic origin with psychotic disorders when recognition 
                                                 
3 Anon. Family care and medical management for Jehovah’s witnesses. Watch Tower. Brooklyn, NY: Watch Tower 
Bible and Tract Society, 1995: 4-5. 
4 Spitzer J. Caring for Jewish Patients. Oxford: Radcliffe, 2003. 
5 Hammad, A. et al. ACCESS: Guide to Arab Culture: Health Care Delivery to the Arab American Community     
Community Health & Research Center Public Health Education and Research Department 
Series of Research Report No. –7-April, 1999  
6 Assadi, D. Do Religions Influence Customer Behavior? Confronting Religious Rules and Marketing Concepts. 
Cahiers du CEREN. 2003. pp. 2-13. 
7 Andeleeb, S.S. Religious Affiliation and Consumer Behavior. Journal of Healthcare and Marketing. 1993 Vol. 13, 
Issue 4.    
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of  culturally  based  differences  between  patients  and  psychiatrists  led  to  modifications  in 
prescribing practices
8.  
An ethical conflict often arises for patients with such religious beliefs as there are over a 
thousand medications with either beef or pork derived gelatin or stearic acid products. A survey 
was designed for a pilot study consisting of 100 patients and physicians to assess their opinion 
about inert ingredients in medications that are restricted for individuals with various religious 
backgrounds. This study showed that 84% patients and 70% of the physicians did not know that 
several  medications  contained  such  products.  Almost  63%  of  the  patients  and  70%  of  the 
physicians found it extremely important for the physician to inform their patients about such 
inert ingredients being present in the prescribed medication
9. 
One of the solutions suggested for such issues is the use of search engines such as the 
British  National  Formulary  (BNF),  which  provides  UK  healthcare  professionals  with 
authoritative and practical information on the selection and clinical use of medicines. This engine 
can be easily used by physicians to find out which medications are derived from blood, alcohol, 
or any other animal derivatives
10. Furthermore, it has been suggested to keep electronic records 
of patients so there can be ‘prescribing alerts’ available for patients with religious restrictions on 
medication products, thereby increasing the level of awareness about such issues.  
Also,  recently  there  has  been  the  emergence  of  a  limited  supply  of  Kosher  (Jewish 
friendly)  and  Halal  (Muslim  friendly)  certified  hard  and  soft  gel  capsules  available  at 
competitive prices. Many manufactures have developed other alternatives such as the vegetarian 
                                                 
8 Opler, L.A. et al. Rethinking Medication Prescribing Practices in an Inner-City Hispanic Mental Health Clinic.  
Journal of Psychiatric Practice. 10(2):134-140, March 2004. 
 
9 Sattar, S.P. The Annals of Pharmacotherapy: 2004; Vol. 38, No. 11, pp. 1830-1835. 
10 Gatrad et al. Archives of Disease in Childhood.2005; 90: 983-984  
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capsules that are made with starch and cellulose instead
11.  There is also the Physician's Desk 
Reference  (PDR),  the  ‘Bible  for  prescription  drugs’,  which  is  available  as  PDR  health 
(http://www.gettingwell.com/drug_info/)  and  also  includes  information  on  over  the-counter 
(OTC) drugs, herbal medications, and nutritional supplements. Generic and brand names are 
provided as well as the uses, side effects, contraindications, special warnings, food and drug 
interactions,  and  dosage  of  the  drug.  Each  entry  includes  images  of  the  medications  for 
identification. However, not many patients or physicians are aware of such sites, references and 
supplies and unless the physician informs the patients of such alternatives, the patients might 
never  know.  Physician–patient  partnerships  are  essential  when  choosing  amongst  various 
therapeutic  options  to  maximize  adherence.  Mutual  collaboration  fosters  greater  patient 
satisfaction, reduces the risks of non-adherence, and improves patients' healthcare outcomes
12. 
All these questions lead back to the interaction and relationship of the physician and 
patient, where the skills and attitudes of the physician are just as essential as the treatment of the 
patient. In states such as Massachusetts, patients have the right to refuse medication if they are 
deemed  competent  to  make  decisions
13.  The  cases  and  studies  show  that  patients  refused 
medication  based  upon  cultural  and  religious  restrictions.  With  such  freedom  available  to 
patients, a look into the history of informed consent is necessary to find out why this problem 
arises the way it does at this time.  
 
 
                                                 
11 Regenstein, J.M., et al. Kosher and Halal in the Biotechnology Era. Applied Biotechnology, Food Science and 
Policy 2003:1(2) 95–107 
12 Martin, L.R. et al. The Challenge of Patient Adherence.  Therapeutics and Clinical Risk Management. 2005: 1(3)     
pp. 189-199 
13 Rogers v Commissioner of Mental Health 2995. Mass Supreme Court, 1983  
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History of Informed Consent:  
Throughout history the relationship between the physician and patient has been evolving 
alongside the shifting role of authority between the physician and patient. The historical roots of 
medical paternalism and non-disclosure to patients in Western Medicine was set early by the 
Greek Hippocratic oath where due to the impotence of the doctors, little was offered to patients 
except  kind  words.  Despite  the  many  recent  judicial  efforts  to  give  patients  a  greater  voice 
through the doctrine of informed consent historically, the doctor-patient relationship has been 
based on a one-way trust. Although a fair amount of knowledge is available about the codes of 
medical ethics and practice and the physician-patient relationship in ancient civilizations, there is 
little evidence that the formalized practice of legally binding informed medical consent existed 
before the late 19th century
14.  
In 1786, Benjamin Rush, one of the most celebrated physicians of the United States, a 
writer,  educator,  and  humanitarian  stressed  the  importance  of  the  physician  maintaining 
unyielding authority and only complying with patients when matters were of little importance. 
He gave great value to the education of the physician and patient to the level where the patient 
could comprehend and agree with the physician’s recommendations. He honored the belief in the 
virtue of silent care and patient compliance. This was the type of relationship that Jay Katz 
termed as the silent care where patient compliance was a necessity and where all the power was 
in the hands of the physicians with the patients playing the submissive role
15.  
Furthermore, in 1803, Thomas Percival introduced the term “medical ethics” where he 
began to view the behavior and interactions of the physician in the society in which he expressed 
                                                 
14 Faden, R.R, Beauchamp, TL. A History of Informed Consent Oxford University Press. 1986 
15 Katz, J. The Silent World of Doctor and Patient. 1984  
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no need of the physician to reveal the truth to the patient if it would prove fatal to him
16. He 
considered disclosure to patients to be harmful and limited freedom of patients was exercised. 
Thomas Percival was an English physician who was one of the most influential medical ethicists. 
He  published  his  Medical  Ethics;  or,  a  Code  of  Institutes  and  Precepts  Adapted  to  the 
Professional  Conduct  of  Physicians  and  Surgeons  which  followed  the  tradition  set  by  the 
Hippocratic Oath. His code stressed the authority and independence of the physician and the 
responsibility  of  the  physician  to  take  care  of  the  sick—giving  the  physician  the  control 
paternalistic role in the doctor-patient relationship.  
In 1847, the American Medical Association adopted Thomas Percival’s Medical Ethics 
and  wrote  and  published  its  very  first  code  of  medical  ethics
17.  This  led  the  way  for  the 
development  and  awareness  of  informed  consent.  For  example,  landmark  cases  such  as  the 
Schloendorff v. NY Hospital case in 1914 stressed the importance of self determination from the 
adult patient of sound mind and therefore imposed the obligation of obtaining consent from 
patients
18.  Slowly the awareness of the need of greater patient autonomy was emerging but not 
enough to pave the way for an end to silent care. 
During World War II, doctors in Nazi Germany were conducting horrifying research on 
prisoners  in  concentration  camps.  This  research  was  done  on  involuntary  participants  who 
usually died as a result of the experiments. After the war, many of these doctors were tried at the 
Nuremberg trials for their crimes. The International community was shocked by the revelations 
of their research. Violations in informed consent in the Nuremberg Trials led to the development 
of the Nuremberg Code in 1947. The Nuremberg Code was the first transnational code of ethics 
used for researchers and subjects across the world and was used to set the stage for all the future 
                                                 
16  Jonsen, AR. A Short History of Medical Ethics. Oxford University Press.1999 
17 Faden, RR. Beauchamp, TL. A History of Informed Consent Oxford University Press. 1986 
18 Schloendorff v. Society of New York Hospital 105 N.E. 92. N.Y. 1914  
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trials
19. This code placed great importance to the voluntary consent of the patient giving him or 
her the capacity to exercise some of his or her rights as free human beings. The 1950s and 1960s 
were  the  eras  where  there  was  the  rising  sense  of  responsibility  of  providing  appropriate 
information to patients and informed consent became more prevalent. 
Additionally,  in  response  to  the  atrocities  committed  by  doctors  in  the  Nazi  era,  the 
World Medical Association, a collaboration of most national medical associations, passed the 
Declaration of Geneva in 1948 which required the physician to not use his expertise against the 
laws of humanities. Just three months after the adoption of this document, the United Nations 
General Assembly adopted another document, the Universal Declaration of Human Rights in 
1948 that was aimed at providing security for the person.  The following year, in October 1949, 
the  Third  General  Assembly  of  the  World  Medical  Association  at  London  adopted  the 
International Code of Medical Ethics of the World Medical Association
20 which required the 
physician to act only in the interest of the patient. This international code served as another 
bridge to expressing the importance of the relationship of the physician and patient and the 
importance of the physicians dealing with the patients honestly and accurately. 
Furthermore, in 1957, the superior court in the city and county of San Francisco declared 
that the duty to disclose the risks of treatments and medications was not a new duty but an 
extension of the originally established duty to disclose information about the nature of treatment 
and consequences to the patients
21. Thus, through these developments, the relationship of the 
physician and patient became more refined with the attempt of making the patient’s consent 
more adequately informed.  
                                                 
19 Annas GJ, Grodin MA. The Nazi Doctors and the Nuremberg Code: human rights in human experimentation. 
New York: Oxford University Press, 1992: 3-11. 
20 World Medical Association Bulletin, vol. 1, no. 3, October 1949, pp.109-111 
21 Salgo v. Leland Stanford Jr. University Bd. Of Trustees 154 Cal.App.2d 560, 317 P.2d Cal.App. 1957  
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By  the  late  1960s  and  early  1970s,  the  emergence  of  the  legal  doctrine  of  informed 
consent led most physicians to recognize both a moral and legal duty to provide for informed 
consent for procedures. In 1972, the Canterbury v. Spence case presented an interesting scenario 
to the realm of informed consent. In this case, the ruling was that the patient’s right to self-
decision is only plausible if the patient has enough information about that matter to make an 
intellectual  choice.  Thus,  this  gave  the  patient  some  rights  to  his  own  determination  in 
treatment
22. If the patient in the 1970s was given the authority to determine his treatment after 
the  physician’s  suggestion,  then  similarly  this  can  be  paralleled  to  the  current  issue  of 
medications with culturally or religiously prohibited inert ingredients. The patients in the case 
study did take charge of their treatment by not complying with consuming medication that may 
be  prohibited  by  religious  or  cultural  laws.  However,  if  physicians  give  their  patients  the 
alternative of taking medications other than the ones with such contents, then the patients would 
be better able to determine their own modes of treatment. However, if physicians take such 
measures, it is important to note that medications must then clearly state their ingredients.  
History of Labeling: 
Another area of extreme importance that relates directly to the labeling of drugs is the 
history of food and drug administration and the concept of the pharmacy. The perception of the 
pharmacy was a relatively new science in the nineteenth and early twentieth centuries as before 
the twentieth century there was no direct federal regulation on drugs or other consumer products. 
There was not a method or means available that could protect the public from harmful drugs or 
make them aware of the contents of the drugs. Efforts to define drugs and determine purity 
contents  and  composition  in  them  developed  with  the  efforts  by  the  US  Pharmacopoeia 
                                                 
22 Canterbury v. Spence., 464 F.2d 772 (DC Cir. 1972)  
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(USP)
23.The  USP  consisted  of  physicians  and  pharmacists,  who  joined  efforts voluntarily  to 
compile a listing of the chemical components of drugs as well as tests to investigate the purity of 
drugs. At the same time, the American Medical Association formed in 1848 and shortly after the 
American Pharmaceutical Association constituted in 1852. During this time, in 1862, President 
Lincoln appointed a chemist to serve in the Department of Agriculture. In 1883, Dr. Harvey W. 
Wiley became chief chemist for the Bureau of Chemistry. His campaigning efforts for a federal 
law were very powerful and immense, such that he is considered the father of the Pure Food and 
Drug Act. This was the beginning of the Bureau of Chemistry, the predecessor of the Food and 
Drug Administration (FDA). The pharmacists from such associations developed the National 
Formulary in 1888
24.   
  However, the official recognition of the National Formulary came in 1906 when Upton 
Sinclair published the book The Jungle which described the unhygienic conditions existent in 
meat packaging. This book and others like Dr. Wiley promoted Congress to pass the Pure Food 
and Drugs Act of 1906 recognizing the US Pharmacopoeia and the National Formulary as an 
official standard in testing purity, testing and strengths of drugs
25. This 1906 law also pertained 
to labeling of drugs where drugs were considered ‘misbranded’ if they contained items such as 
an alcohol, opium, morphine, and or cocaine.  
The scientists of the Bureau of Chemistry became involved in this process by running 
tests to purify the drugs. Through this law, with the combination of the performance of tests by 
the Bureau of Chemistry, drug manufacturing improved as well as the recognition of the need to 
                                                 
23 Sonnedecker, G. The Founding Period of the U.S. Pharmacopoeia. Pharm Hist. 1994; 36(3):103-22.  
24 Sonnedecker, Glenn. 1970. Contribution of the Pharmaceutical Profession toward Controlling the Quality of 
Drugs in the Nineteenth Century. In Safeguarding the Public: Historical Aspects of Medicinal Drug Control, edited 
by J. B. Blake. Baltimore: Johns Hopkins University Press. 
25 Temin, Peter. 1980. Taking Your Medicine: Drug Regulation in the United States. Cambridge, Mass.: Harvard 
University Press  
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provide  more  information  about  drug  contents.  Furthermore,  the  Sherley  Amendent  of  1912 
clearly banned fraud and deceitful claims about the contents of the drugs. During this time, the 
FDA’s role as a monitoring agent in identifying drugs became affirmed. In 1927, the Bureau of 
Chemistry regrouped to become the Food, Drug, and Insecticide Administration, which in 1930 
changed its name to the Food and Drug Administration
26. Some of the specific functions of the 
FDA  included  regulating  data  on  food  labels,  overseeing  clinical  trials  for  new  drugs  and 
investigating consumer complaints about food and drugs. The latter was extremely important as 
seen in the case of Massengel. 
  In 1937, Massengel, a pharmaceutical company of Bristol, Tennessee introduced a new 
drug with sulfanilamide, the
 first sulfa antimicrobial drug. In this drug diethylene glycol was 
used
 as the solvent in the formulation of a liquid preparation of
 sulfanilamide known as Elixir 
Sulfanilamide. This solvent diethylene glycol proved fatal for people and as a result hundreds of 
people, mostly children, died from an untested elixir
27. The Elixir Sulfanilamide disaster of 1937 
was one of the most
 consequential mass poisonings of the twentieth century. One hundred five 
patients died from its therapeutic use. Under the existing drug regulations, pre-marketing toxicity 
testing  was  not  required
28.This  tragedy  engendered  the  way  for  Congress  to  pass  the  1938 
Federal Food, Drug, and Cosmetic Act—regulatory
 legislation that for the first time required 
drug manufacturers
 to show drug safety before public sale and distribution. It remains the basic 
law today. The relationship
 between the pharmaceutical industry and the government and its
 
effect on the practice of medicine were significantly changed
 by this event
29.  
                                                 
26 Kleinfeld, Vincent A. 1970. Commentary and participation in Discussion. In Safeguarding the Public: Historical 
Aspects of Medicinal Drug Control, edited by J. B. Blake. Baltimore: Johns Hopkins University Press 
27 Krauss, Michael I. 1996. Loosening the FDA’s Drug Certification Monopoly: Implications for Tort Law and 
Consumer Welfare. George Mason Law Review 4 (spring): 457–83. 
28 Wax, PM. Elixirs, diluents and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med. 
1995 Mar 15;122(6):456-61. 
29 Jackson CO. Food and Drug Legislation in the New Deal. Princeton, NJ: Princeton University Press; 1970:151-74  
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The 1938 law mandated that all new drugs be tested and proven for safety before being 
released  in  the  market.  Formula  disclosures  of  all  active  ingredients  became  a  requirement. 
Directions  on  how  to  use  the  medications  as  well  as  the  prescriptions  of  drugs  were  also 
required.  It  also  banned  dangerous  drugs  and  misbranding  of  drugs  as  well
30.  Such  strict 
regulations  increased  the  practice  of  requiring  prescriptions  for  certain  drugs.  This  proved 
evolutionary in the way patients obtained medication. In turn, it engendered a change in the 
patient physician relationship as well. This occurred during the time when Durham-Humphrey 
Amendment in 1951, drew a concise legal distinction between prescription-only and over the 
counter  (OTC)  drugs,  and  authorized  the  FDA  to  classify  drugs  accordingly
31.  With  this 
amendment,  certain  drugs  could  be  prescribed  only  by  doctors.  This  gave  the  role  of  the 
physician great authority as a patient’s right to use to a specific drug was not accessible through 
money but required visitation to the doctor. This incident with the elixir drug had a multifaceted 
impact in general. It brought greater awareness of properly monitoring labeling of drugs yet it 
also caused an imbalance in the physician patient relationship as the dependence on the doctor 
was further legitimated by complicating the patient’s right to gain information about the drugs by 
the labeling and advertising controls
32. Thus, the freedom of the patient to self-medicate was 
violated due to events like the elixir incident which had left hundreds dead while monitoring 
controls on drugs before getting on market improved. 
Although,  great  improvements  were  implemented  through  the  1938  law,  drastic 
limitations in regulations still remained. Proof of the efficacy of drugs was not yet required, 
                                                 
30 Federal Food, Drug, and Cosmetic Act 1938. Public Law 717,52, Stat 1040; 25 June 1938. 
31 Wardell, W. M., and L. Lasagna. 1975. Regulation and Drug Development. Washington, D.C.: American 
Enterprise Institute for Public Policy Research. 
32 Young, James Harvey. 1970. Drugs and the 1906 Law. In Safeguarding the Public: Historical Aspects of 
Medicinal Drug Control, edited by J. B. Blake.Baltimore: Johns Hopkins University Press  
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human clinical trials were conducted poorly, drugs studied in pre-marketing clinical trial were 
not reviewed, and animal testing was not standardized
33.  
It took another twenty three years before any significant attempt was implemented to 
make drug safety regulations stronger. Despite the efforts of senators, another drug calamity like 
that of Elixir Sulfanilamide Disaster 1937 which left hundreds dead further emphasized and 
further  continued  reform  in  the  regulation  of  drugs.  During  this  period,  it  was  the  drug 
thalidomide  that  caused  the  tragedies.  In  1962,  a  new  sleeping  pill  called  thalidomide  was 
produced only to discover that it caused birth defects in thousands of babies in Western Europe. 
Due to the strict regulations set in 1938 and the role of Dr. Francis Kelsey, an FDA official who 
prevented  this  drug  from  getting  on  the  market,  thalidomide  was  prevented  from  causing 
disasters in the United States
34.  
  However, despite this regulation, thalidomide was manufactured from a pharmaceutical 
company, Merrell Pharmaceutical and supplied to many physicians in the United States. Through 
this, thalidomide was distributed amongst 20,000 patients, including pregnant women
35.  This 
was a clear indication that more strict laws of regulation were still required to prevent such 
incidents from occurring. Thus, in 1962, more new Drug Amendments were passed to ensure 
drug efficacy and greater drug safety. These laws reduced the choices of the doctors and patients 
and expanded those of the FDA. The FDA was required to closely monitor drug development at 
all stages. Animal testing became a mandatory process before human trials were conducted and 
                                                 
33 Janssen WF. FDA since 1938: The major trends and developments. Journal of Public Law. 1964; 13:205-21. 
34 McFadyen RE. Thalidomide in America: a brush with tragedy. Clio Med. 1976; 11:79-93. 
35 Thalidomide. Public Health Report. 1962; 77:946  
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time  limitations  on  drugs  were  removed
36.  Due  to  the  removal  of  time  limitations,  drug 
developments in general lengthened.  
In 1966, the Fair Packaging and Labeling Act was passed that required all consumer 
products  to  be  honestly  and  informatively  labeled  on  foods,  drugs,  cosmetics,  and  medical 
devices
37. In 1970, the FDA required the first patient package insert. In 1972, this labeling was 
further promoted to be used for over the counter drugs when the FDA began reviewing these 
drugs for safety and effectiveness. With such lengthy procedures in regulations and approvals, it 
is hard to fathom how long it will take for the industry to come up with solutions of providing 
alternative  drugs  or  improve  labeling  more  efficiently  for  people  with  different  cultural 
backgrounds and religious beliefs.  
As  years  passed  with  such  strict  regulations,  by  the  time  it  was  the  1980s,  the  time 
spanned for drug approval reached almost twenty years
38. This length posed a serious problem 
for the patients who were in dire need of those drugs for their conditions.  Awareness of the 
patient’s concerns led to a reform in the approval process. At the same time, in 1983, the Orphan 
Drug Act was also created to promote the development of drugs for rare diseases that affected a 
very small population of only under 200,000 people in the United States. Congress implemented 
this act to ensure that the products with low commercial value but useful in saving lives would 
also be produced in the market. To promote this act, tax breaks were provided and privileges 
were given to the companies that sponsored the production of such drugs
39. Orphan drugs have 
                                                 
36 Schnee JE. Governmental control of therapeutic drugs: intent, impact and issues. In: Lindsay CM, Caglarcan E, 
eds. The Pharmaceutical Industry: Economics, Performance, and Government Regulation. New York: Wiley; 
1978:9-14 
37 Meadows, M. Promoting Safe and Effective Drugs for 100 Years. FDA Consumer Magazine. Vol 40 (1) | January-
February 2004 
38 Statman, Meir. 1983. Competition in the Pharmaceutical Industry: The Declining Profitability of Drug 
Innovation. Washington, D.C.: American Enterprise Institute for Public Policy Research. 
39 Haffner, M. Orphan Drug Development Update. Drug Information Journal, Vol. 30, pp. 29–34, 1996  
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continued  to  be  produced  since  and  have  been  immensely  successful  as  well.  It  would  be 
interesting to see what would happen if congress lobbied for a similar type of act that provided 
privileges and tax breaks for companies that developed alternative drugs specifically for people 
with specific religious and or culture beliefs.  It could be that the way the Orphan Drug Act has 
remained  successful,  such  an  initiative  might  be  successful  as  well  and  prevent  relapse  of 
diseases of many patients in the population. 
Many other acts were passed during the 1980s such as the Waxman-Hatch Act of 1984 
which protected time loss on patent drugs before generic ones could be produced and the Drug 
Export Amendment Act of 1986 that attempted to protect drug loss by preventing unapproved 
drugs from being exported. However, it was not until the 1990s that labeling contents became 
official. In 1990, the Nutritional Labeling and Education Act was passed
40. Finally, labeling of 
nutritional products on most food products except meat and poultry were made a requirement 
after being illegal before the 1970s
41. This was an integral step in building awareness of nutrient 
content in products. This act gave FDA authority to allow health claims on food products and 
dietary supplements which led to the passing of the Dietary Supplement Health and Education 
Act of 1994 by President Clinton
42. This act helped ensure that safe and appropriately labeled 
products were available to those who wanted to use them.  
To enable a more expedited review of drugs, the FDA Modernization Act of 1997 was 
passed
43.  Labeling  for  over  the  counter  drugs  became  standardized  in  1999  similar  to  the 
nutritional facts about foods. Furthermore, the sources of information on the inactive ingredients 
                                                 
40 http://www.fda.gov/opacom/backgrounders/foodlabel/newlabel.html  
41 Viscusi, W.K.1996. "Regulatory Reform and Liability for Pharmaceuticals and Medical Devices," Advancing 
Medical Innovation: Health, Safety and the Role of Government in the 21st Century, The Progress and Freedom 
Foundation, February 7, 1996: 79-102. 
42 Pinco, R. G & Rubin P.D. 1996. Ambiguities of the Dietary Supplement Health and Education Act of 1994. Food 
and Drug Law Journal 51: 383–405. 
43 http://www.fda.gov/cdrh/modact/modern.html  
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in drugs became available and got listed on the label of every over the counter drugs and in the 
package  inserts  which  is  now  available  from  a  pharmacy,  PDR,  and  other  websites  for 
prescriptions drugs.  In 2004, the Food Allergy Labeling and Consumer Protection Act was 
passed to protect consumers with food allergies such as with peanuts, tree nuts, soybeans, fish, 
and  more
44.  Just  recently  in  2005,  the  formation  of  the  Drug  Safety  Board  took  place  with 
representatives from the National Institute of Health, FDA staff, and representatives from the 
veteran’s association. This board will be used for protecting the safety of patients by providing 
more information about the drugs to health professionals and patients about drug safety issues 
and regulating drugs already on the market
45.  
The  history  of  labeling  has  been  one  of  many  lengthy  procedures  and  time  span. 
However, goals were set, achieved, and implemented although it took a long time. Similarly, if 
measures are taken to set goals to provide better alternatives of medications for patients with 
special dietary restrictions, the inequity in prescription and compliance would narrow.   
Discussion:   
  The  evolving  relationship  of  the  physician  and  patient  has  become  stagnant  due  to 
multiple  issues  raised  in  the  system  today  that  have  also  been  witnessed  in  the  past.  With 
tragedies like the elixir incident of 1937, physicians have gained more authority giving patients 
even less freedom and autonomy to develop a more informed dialogue with their doctors and get 
complete thorough care. This authority has created a gap in the system. 
Thus, cultural competence, greater awareness of available drugs and their alternatives, a 
more informed dialogue between the patient and physician can foster a balance and assist in 
diminishing the gaps present in the current system. This balance between religious and clinical 
                                                 
44 http://www.fda.gov/fdac/features/2006/106_fdawork.html 
45 http://www.newscientist.com/article.ns?id=dn7017  
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needs is necessary. The respect for patient autonomy has a central role in the justification and 
function  of  informed  consent  requirements.  Historically,  landmark  cases  such  as  the 
Schloendorff v. NY Hospital case in 1914 have continuously emphasized the importance of self 
determination in patients.  This emphasis has evolved into many areas that need greater attention 
such as that with patient adherence to medications. 
However, how much is enough and how much should the clinician know to be able to 
provide the patient with the most appropriate treatment and inform him thoroughly about it? 
How  much  information  should  be  disclosed  to  the  patient?                                                      
  Lidz, Appelbaum, and Meisel suggest that the problems of informed consent root from 
the  way  informed  consent  is  implemented.  They  suggest  trying  the  process  model  which 
emphasizes active participation of the patient in medical decision-making
46. This is somewhat 
similar to what Jay Katz described as the informed dialogue between the patient and physician 
where the patient is accepted as a valued member of the healthcare team, one who has choice and 
authority to play a role in the decisions.  
Another report by Veatch has questioned if informed consent is even appropriate in the 
medical decision making process. This report has argued that it is impossible for physicians to 
come up with the appropriate treatment without active patient participation which mirrors the 
process model and the idea of informed dialogue.  This report’s contribution to informed consent 
is based on the idea that the patient physician relationship should be based on deep values where 
the healthcare systems reorganize around particular orientations such as Catholic, holistic, and 
more.  This  would  make  it  easier  for  patients  to  choose  physicians  who  understand  their 
                                                 
46 Lidz CW, Appelbaum PS, Meisel A. "Two Models of Implementing Informed Consent." Archives of Internal 
Medicine, June 1988. Vol 148, 1385-1389  
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backgrounds and beliefs, and would thereby reduce the gap of nonadherence to medications and 
making  the  decision  making  process  easier
47.  Although,  ideally  this  would  result  in  fewer 
misunderstandings between the unique relationship of the patient and physician, it is not always 
possible. General cultural competency, awareness of backgrounds could potentially be one of the 
keys to better patient compliance to medications.   
 Is  it  possible  to  control  the  inactive  ingredients  in  drugs  and  get  all  the  related 
information from the labeling of the drugs instead of dependence on the physician? Well for one, 
there are now sources of information on the inactive ingredients in drugs. They are listed on the 
label of every over the counter drug and are listed in every package insert—which is usually 
available from the pharmacy, PDR, or website—for prescription drugs. Similarly, in Australia, 
pharmaceutical  manufacturers  include  in  depth  declarations  in  the  drug  packages  about  the 
source of materials used in the preparation of their drugs
48. So in a way, patients do now have 
some more accessibility to obtaining information about the complete contents of their drugs. It 
may not be as obvious as people hope, but if efforts are made, and time is taken to read the 
inserts and call up the companies, they can eventually figure out what ingredients are in the 
drugs. 
With regards to controlling the inactive ingredients in drugs, however, there are several 
issues with labeling that need to be taken into consideration. First, the FDA has no authority to 
require a drug company to not use a type of inactive ingredient unless the ingredient is safe.
49 
Furthermore, the FDA cannot require that a pharmaceutical company distribute two or more 
types of drugs, with different inactive ingredients. With this set up, it is indeed unclear how 
many different types of inactive ingredients would have to be required in order to satisfy all of 
                                                 
47 Veatch RM. "Abandoning Informed Consent." Hastings Center Report, 1995. 25(2):5-12. 
48 Anesthesia for Vegetarians: Anesthesia. 2005 May;60(5):520-1 
49 http://www.fda.gov/Drugs/InformationOnDrugs/ucm080123.htm  
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the diverse religions and views of the United States. This would also pose various challenges if 
some  religions  were  given  priority  over  others  in  this  matter.  If  somehow  this  process  was 
encouraged and passed—as seen by the history of labeling of drugs, this process in itself would 
require many years before implementation would actually occur. After the passing of the 1938 
Food Drug and Cosmetic Act, it took another twenty years before any other drug regulation was 
implemented. Similarly, it would not be surprising if such a huge gap occurs before FDA is ever 
granted  this  approval,  although  it  is  very  unlikely  that  it  is  even  possible.   
   Moreover, one of the reasons for this is because a drug manufacturer is not permitted to 
change inactive ingredients in a prescription drug or market two forms of the same drugs with 
inactive ingredients without extensive testing. This testing would cost millions of dollars and 
then obtaining FDA approval would take another long period of time. This would be very costly. 
It is hard to predict who would pay for this process. Even if the religious groups did decide to 
contribute to this, would this be something feasible and efficient to do? Is just having thorough 
label inserts enough? How can cultural or religious non adherence be prevented? 
Although  attempts  have  been  made  to  end  the  silence  in  the  patient  and  physician 
relationship throughout history, elements of silent care still remain, such as nonadherence to 
medications  due  to  unawareness  and  lack  of  cultural  competency.  This  demonstrates  their 
detrimental effect on proper patient care.  
With the advent of sophisticated technology playing an integral role in medical care, 
there is a greater need of informed dialogue to exist between patients and physicians. This is 
necessary so that physicians can respect the needs of the patient and the autonomy of the patient 
can be restored and true informed consent exercised—a system where patients and doctors can 
communicate more and the paternalistic role of the doctor is transferred into that of a friend—a  
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relationship of transference and counter transference. Purity in transference is needed to improve 
this relationship. This dialogue does not rest only between the patient and physician.   
However,  the  rise  of  managed  care  organizations  prevents  doctors  from  giving  full 
disclosure. Now even if a doctor wants to inform the patient thoroughly, time limiting factors 
prevent him from proper informed dialogue. The financial pressure placed on the doctors limits 
their willingness to understand the patient. The more time the doctors spend with one patient 
result in loss net income to the higher administration of the hospital. The more patients the 
doctors see, the higher the income.  This also results in doctors being reluctant to view their 
patients in a holistic manner and restricts them to hold only the necessary conversation.  Higher 
administration needs to be supportive of the doctors by giving them the flexibility to build a 
proper relationship. 
This is also where the help of the pharmaceutical companies come in. In the age where 
electronic records are used and effective, innovative technology and methods could possibly be 
considered. If the FDA and or drug companies can somehow figure out an electronic system that 
can give alerts about ingredients for various religious groups, or provide alternative vegetarian 
drugs, and formulate ways to have medical information about the drugs more accessible to the 
public—such as in the form of drug advertisements to inform the patients and physicians of the 
contents—then maybe the problem of non compliance to medications due to inert ingredients can 
be prevented in the future. How feasible these ideas and methods are, one cannot predict but 
continuous awareness about this problem can help make strides in this issue.  
In the near future, it would be interesting to find out if increasing awareness of this 
problem and finding a solution to this type of non-adherence to medication would increase public 
health awareness and the overall public health in various states. 